By Turna Ray
Consumer genomics firms that were the subject of last week's damaging Government Accountability Office investigation into their practices went on the offensive this week and accused the federal agency's report of being "flawed," "misleading," and "slanderous."
At the same time, Navigenics, 23andMe, and Decode Genetics all welcomed greater regulatory oversight for the nascent industry and vowed to work with the US Food and Drug Administration to develop standards for their offerings.